Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs
Open Access
- 1 March 1999
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (12), 7987-7992
- https://doi.org/10.1074/jbc.274.12.7987
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Chemotherapeutic drug‐induced apoptosis in human leukaemic cells is independent of the Fas (APO‐1/CD95) receptor/ligand systemBritish Journal of Haematology, 1998
- FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling ComplexCell, 1996
- Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell DeathCell, 1996
- FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced ApoptosisJournal of Biological Chemistry, 1996
- Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivoEuropean Journal of Immunology, 1995
- Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signalsCell, 1995
- FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosisCell, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell, 1991
- A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.The Journal of Experimental Medicine, 1989